A Brief Review on the Potential of Psychedelics for Treating Alzheimer’s Disease and Related Depression
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241512513 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Alexander Pilozzi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Neurochemistry Laboratory, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. Hauptthemen laut MEDLINE: Hallucinogens, Alzheimer Disease. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIA NIH HHS, NIH HHS.
Themen: Depression, Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD), the most common form of senile dementia, is poised to place an even greater societal and healthcare burden as the population ages. With few treatment options for the symptomatic relief of the disease and its unknown etiopathology, more research into AD is urgently needed. Psychedelic drugs target AD-related psychological pathology and symptoms such as depression. Using microdosing, psychedelic drugs may prove to help combat this devastating disease by eliciting psychiatric benefits via acting through various mechanisms of action such as serotonin and dopamine pathways. Herein, we review the studied benefits of a few psychedelic compounds that may show promise in treating AD and attenuating its related depressive symptoms. We used the listed keywords to search through PubMed for relevant preclinical, clinical research, and review articles. The putative mechanism of action (MOA) for psychedelics is that they act mainly as serotonin receptor agonists and induce potential beneficial effects for treating AD and related depression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurochemistry Laboratory, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
- Depression Clinical & Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
ORCID-Profile: Simmie Foster, David Mischoulon, Xudong Huang
Förderung
- NIGMS NIH HHS
- NIA NIH HHS
- NIH HHS
- NIH
Zitieren
APA
Pilozzi, A., Foster, S., Mischoulon, D., Fava, M., & Huang, X. (2023). A Brief Review on the Potential of Psychedelics for Treating Alzheimer’s Disease and Related Depression. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241512513
Vancouver
Pilozzi A, Foster S, Mischoulon D, Fava M, Huang X. A Brief Review on the Potential of Psychedelics for Treating Alzheimer’s Disease and Related Depression. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241512513
BibTeX
@article{Pilozzi2023,
author = {Pilozzi, Alexander and Foster, Simmie and Mischoulon, David and Fava, Maurizio and Huang, Xudong},
title = {A Brief Review on the Potential of Psychedelics for Treating Alzheimer’s Disease and Related Depression},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241512513}
}
EUVIMED